Status: Recruiting
Drug-Drug Interaction Study of ABP-671 in Gout Patients
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.
Participants needed: 20
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Atom Therapeutics Co., LtdUpdated: Apr 14, 2026Locations: 1
Eligibility criteria
Adults 18-75 years with clinical diagnosis of gout. [+3]
Clinically significant hepatic impairment. [+2]